These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 8387790)

  • 21. In vitro activity of KRM-1648, either singly or in combination with ofloxacin, against Mycobacterium ulcerans.
    Dhople AM
    Int J Antimicrob Agents; 2001 Jan; 17(1):57-61. PubMed ID: 11137650
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro susceptibility of Mycobacterium tuberculosis to ofloxacin and ciprofloxacin in combination with rifampin and isoniazid.
    Casal M; Gutierrez J; González J; Ruiz P
    Chemioterapia; 1987 Dec; 6(6):437-9. PubMed ID: 3124964
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multivariate analysis of the activity of rifamycins against rapidly growing Mycobacteria, to define an in vitro screening model for their activity against mycobacterium leprae.
    Pattyn SR; Hébrant F
    Arzneimittelforschung; 1980; 30(12):2099-103. PubMed ID: 7011330
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro activities of aminoglycosides, lincosamides, and rifamycins against Mycobacterium leprae.
    Franzblau SG
    Antimicrob Agents Chemother; 1991 Jun; 35(6):1232-4. PubMed ID: 1929269
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Determination of in vitro synergy when three antimicrobial agents are combined against Mycobacterium tuberculosis.
    Bhusal Y; Shiohira CM; Yamane N
    Int J Antimicrob Agents; 2005 Oct; 26(4):292-7. PubMed ID: 16150578
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Minimal inhibitory concentrations of rifabutin, ciprofloxacin, and ofloxacin against Mycobacterium tuberculosis isolated before treatment of patients in Taiwan.
    Chen CH; Shih JF; Lindholm-Levy PJ; Heifets LB
    Am Rev Respir Dis; 1989 Oct; 140(4):987-9. PubMed ID: 2552883
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multidrug-resistance to dapsone, rifampicin, and ofloxacin in Mycobacterium leprae.
    Cambau E; Perani E; Guillemin I; Jamet P; Ji B
    Lancet; 1997 Jan; 349(9045):103-4. PubMed ID: 8996430
    [No Abstract]   [Full Text] [Related]  

  • 28. Rifabutin and rifapentine compared with rifampin against Mycobacterium leprae in mice.
    Pattyn SR
    Antimicrob Agents Chemother; 1987 Jan; 31(1):134. PubMed ID: 3032088
    [No Abstract]   [Full Text] [Related]  

  • 29. Activity of ofloxacin against Mycobacterium leprae in the mouse.
    Grosset JH; Guelpa-Lauras CC; Perani EG; Beoletto C
    Int J Lepr Other Mycobact Dis; 1988 Jun; 56(2):259-64. PubMed ID: 3045223
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Comparative in vitro activities of rifabutin and rifampicin against various mycobacteria using 7H10 agar and 1% Ogawa egg media].
    Sato K; Saito H; Tomioka H
    Kekkaku; 1988 Sep; 63(9):601-4. PubMed ID: 2854588
    [No Abstract]   [Full Text] [Related]  

  • 31. In-vitro activity of rifabutin against rifampicin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations.
    Cavusoglu C; Karaca-Derici Y; Bilgic A
    Clin Microbiol Infect; 2004 Jul; 10(7):662-5. PubMed ID: 15214882
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Intra-macrophagic activity of antibiotics combinations against Mycobacterium marinum].
    Gevaudan MJ; Bollet C; Mallet MN; de Micco P
    Pathol Biol (Paris); 1991 May; 39(5):436-41. PubMed ID: 1652732
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combinations of rifampin or rifabutine plus ethambutol against Mycobacterium avium complex. Bactericidal synergistic, and bacteriostatic additive or synergistic effects.
    Heifets LB; Iseman MD; Lindholm-Levy PJ
    Am Rev Respir Dis; 1988 Mar; 137(3):711-5. PubMed ID: 2830814
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [MICs and MBCs of levofloxacin, clarithromycin, and KRM-1648 for Mycobacterium tuberculosis and M. avium complex residing in MONO-MAC-6 human macrophage-like cell and A-549 human type II alveolar epithelial cell lines].
    Sato K; Ogasawara K; Akaki T; Tomioka H
    Kekkaku; 1999 Jul; 74(7):571-7. PubMed ID: 10481412
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro activity of linezolid in combination with doxycycline, fosfomycin, levofloxacin, rifampicin and vancomycin against methicillin-susceptible Staphylococcus aureus.
    Sahuquillo Arce JM; Colombo Gainza E; Gil Brusola A; Ortiz Estévez R; Cantón E; Gobernado M
    Rev Esp Quimioter; 2006 Sep; 19(3):252-7. PubMed ID: 17099793
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro synergistic effect of doxycycline & ofloxacin in combination with ethanolic leaf extract of Vangueria spinosa against four pathogenic bacteria.
    Chatterjee SK; Bhattacharjee I; Chandra G
    Indian J Med Res; 2009 Oct; 130(4):475-8. PubMed ID: 19942754
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of brodimoprim on Mycobacterium leprae in vitro and in mouse foot-pads.
    Dhople AM; Ortega I; Seydel JK; Gardner GD
    Indian J Lepr; 1990; 62(1):76-86. PubMed ID: 2193064
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparison of the bactericidal activity of a series of rifampicins against Mycobacterium leprae.
    Pattyn SR
    Arzneimittelforschung; 1982; 32(1):15-7. PubMed ID: 7037013
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activity of sparfloxacin against Mycobacterium leprae measured by the proportional bactericidal test.
    McDermott-Lancaster RD; Banerjee DK
    Int J Lepr Other Mycobact Dis; 1993 Dec; 61(4):605-8. PubMed ID: 8151193
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro and in vivo activities of ofloxacin against Mycobacterium leprae infection induced in mice.
    Saito H; Tomioka H; Nagashima K
    Int J Lepr Other Mycobact Dis; 1986 Dec; 54(4):560-2. PubMed ID: 3546546
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.